Curaleaf (OTCMKTS:CURLF) Cut to “Hold” at Cormark

Cormark downgraded shares of Curaleaf (OTCMKTS:CURLFFree Report) from a moderate buy rating to a hold rating in a research report sent to investors on Thursday,Zacks.com reports.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $6.25 price target on shares of Curaleaf in a report on Thursday, August 8th.

Check Out Our Latest Analysis on CURLF

Curaleaf Stock Down 5.5 %

OTCMKTS CURLF opened at $2.13 on Thursday. Curaleaf has a 1-year low of $2.07 and a 1-year high of $6.40. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -7.34 and a beta of 0.86. The stock’s 50 day moving average is $2.97 and its two-hundred day moving average is $3.80. The company has a current ratio of 1.09, a quick ratio of 0.50 and a debt-to-equity ratio of 0.83.

Curaleaf (OTCMKTS:CURLFGet Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $342.29 million during the quarter, compared to the consensus estimate of $344.57 million. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.35%. Equities analysts forecast that Curaleaf will post -0.24 earnings per share for the current fiscal year.

About Curaleaf

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Featured Articles

Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.